Saturday 17 October 2026
Export CRVO’s income statement to Excel — free account
CervoMed Inc.
CRVO Healthcare Biotechnology
CervoMed Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, down 58.9% from fiscal 2024. In the quarter to June 2026, revenue fell 99.6%, EPS grew 8.57% and free cash flow fell 6.20%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.24
0.01
−0.44%
Follow CRVO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
12.15 | 17.83 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(11.58) | (10.86) | — | — | |
P/B ratio |
2.88 | 3.92 | — | — | |
Price to Tangible BV |
4.31 | 7.45 | — | — | |
EV/Sales |
9.83 | 15.86 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(2.43) | (2.71) | — | — | |
EV/FCF |
(2.39) | (2.66) | — | — | |
Quick Ratio |
6.23 | 4.57 | 2.87 | 8.22 | |
Current Ratio |
6.66 | 4.91 | 3.36 | 8.57 | |
Net Debt/EBITDA |
3.39 | 2.50 | 1.59 | 3.73 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.16 | 0.12 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.81 | 1.01 | 1.05 | |
Research and Development Expense of Revenue |
1,872.41% | 67,013.79% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
721.11% | 28,850.57% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
90.42% | 3,433.33% | 0.00% | 0.00% | |
Graham Net Nets |
0.35 | 0.26 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(35.85%) | (37.72%) | — | — | |
Free Cash Flow Yield |
(33.88%) | (33.44%) | — | — | |
Revenue per Share |
0.03 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.70) | (0.73) | (0.87) | (0.68) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.70) | (0.73) | (0.87) | (0.68) | |
Cash per Share |
2.95 | 2.31 | 1.40 | 2.43 | |
Shareholders Equity per Share |
2.81 | 2.02 | 1.15 | 2.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.81 | 2.02 | 1.15 | 2.24 | |
Free Cash Flow |
(6.47) | (6.58) | (8.02) | (6.92) | |
Working Capital |
26.01 | 18.22 | 10.62 | 22.96 | |
Net Current Asset Value |
26.01 | 18.22 | 10.62 | 22.96 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
0.81 | 1.34 | — | — | |
Average Payables |
1.22 | 1.48 | 2.07 | 1.27 | |
Average Assets |
39.75 | 32.98 | 26.85 | 32.04 | |
Average Common Equity |
35.82 | 28.71 | 22.63 | 28.20 |
Columns are period end dates